Market Insights
Our life sciences market insights offer posts for clients seeking exceptional hires.
Biotech Executive Compensation Mix by Company Stage (10/23/2026) - How much an executive is paid is only part of the compensation decision. The balance among salary, cash incentives, and equity also matters, particularly when a biotechnology company is preparing for its next stage of development. GeneCoda® examined FY2025 CEO and CFO compensation across clinical-stage, late-stage/near-commercial, and commercial/transition public biotech companies. In this research cohort, … Continue reading "Biotech Executive Compensation Mix by Company Stage"
When the science is right, but the story is wrong (10/23/2026) - A life sciences company can have compelling science, a strong intellectual property position, promising data, and a highly respected scientific team, yet still struggle to convince the people whose support it needs most. Investors hesitate. Potential partners ask more questions. Candidates remain uncertain about the opportunity. Employees hear different versions of the company’s priorities depending … Continue reading "When the science is right, but the story is wrong"
What happens when everyone in the executive team is a specialist? (10/16/2026) - A life sciences company can have an impressive executive team on paper and still struggle to make good decisions. The Chief Scientific Officer understands the science. The Chief Medical Officer understands development. The Chief Financial Officer understands capital. The Chief Commercial Officer understands the market. The Chief Operating Officer understands execution. Everyone is accomplished. Everyone … Continue reading "What happens when everyone in the executive team is a specialist?"For additional posts, please see our Blog.
↓ Stay connected with GeneCoda® on LinkedIn for updates and insights.
